Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Gattei

Showing results (161-170 of 190) with videos related to

Pageof 19
Sort By:
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Leukemia|December 17, 2024
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirementJana Nabki, Bashar Al Deeban, Abel Mehari Sium, et al.
Hematological Oncology|July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Blood|February 2, 2020
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expressionErika Tissino, Federico Pozzo, Dania Benedetti, et al.
The Journal of Experimental Medicine|January 6, 2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemiaErika Tissino, Dania Benedetti, Sarah E M Herman, et al.
Haematologica|October 5, 2019
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemiaJared A Cohen, Francesca Maria Rossi, Antonella Zucchetto, et al.
Blood|August 16, 2015
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, et al.
The Journal of Pathology|November 3, 2020
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancerDavide Viotto, Francesca Russo, Ilaria Anania, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasAlberto J Arribas, Francesca Guidetti, Eleonora Cannas, et al.
Pageof 19

Showing results (161-170 of 190) with videos related to

Sort By:
Pageof 19
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Leukemia|December 17, 2024
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirementJana Nabki, Bashar Al Deeban, Abel Mehari Sium, et al.
Hematological Oncology|July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Blood|February 2, 2020
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expressionErika Tissino, Federico Pozzo, Dania Benedetti, et al.
The Journal of Experimental Medicine|January 6, 2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemiaErika Tissino, Dania Benedetti, Sarah E M Herman, et al.
Haematologica|October 5, 2019
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemiaJared A Cohen, Francesca Maria Rossi, Antonella Zucchetto, et al.
Blood|August 16, 2015
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, et al.
The Journal of Pathology|November 3, 2020
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancerDavide Viotto, Francesca Russo, Ilaria Anania, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasAlberto J Arribas, Francesca Guidetti, Eleonora Cannas, et al.
Pageof 19